Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of GEMOX Combined With Donafenib and Tislelizumab as First-line Treatment in Biliary Tract Cancer

NCT04979663 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04979663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04979663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of GEMOX Combined With Donafenib and Tislelizumab as First-line Treatment in Biliary Tract Cancer
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 1, 2020
Completion date
June 30, 2022
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma